Literature DB >> 14585889

Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound.

L E Bath1, W H B Wallace, M P Shaw, C Fitzpatrick, R A Anderson.   

Abstract

BACKGROUND: Treatment of cancer during childhood may result in loss of primordial follicles from the ovary.
METHODS: Ten cancer survivors and 11 controls with regular menstrual cycles, in addition to 10 cancer survivors and 10 controls taking the combined oral contraceptive pill (COCP) were recruited. Subjects were investigated on days 3-5 of a menstrual cycle, or week 3 of COCP administration before and 24 h after administration of 225 IU FSH.
RESULTS: Serum FSH levels were elevated in cancer survivors with regular menstrual cycles (7.5 +/- 1.4 versus 4.2 +/- 0.3 IU/l; P = 0.02), while anti-Müllerian hormone (AMH) levels were lower (13.0 +/- 3.0 versus 21.0 +/- 3.4 pmol/l; P < 0.05). Other hormone levels were unchanged. Ovarian volume was smaller in cancer survivors than controls (3.0 +/- 0.5 versus 5.0 +/- 0.8 ml; P < 0.05), but antral follicle count (AFC) was similar. During COCP administration, inhibin B remained undetectable in six cancer survivors after FSH administration, whereas all controls showed a rise in inhibin B levels. The AFC was lower in cancer survivors than in controls (4.2 +/- 0.8 versus 7.2 +/- 0.8; P = 0.02). Ovarian volume was low in both groups, but did not differ between them.
CONCLUSIONS: The study results demonstrate both hormonal and biophysical evidence of partial loss of the ovarian reserve in young cancer survivors. This was detected both in women with normal menstrual cycles and during COCP administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585889     DOI: 10.1093/humrep/deg473

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  62 in total

1.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

2.  Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal women.

Authors:  Muhammad Faisal Aslam; Zaher O Merhi; Safaa Ahmed; Oumar Kuzbari; David B Seifer; Howard Minkoff
Journal:  Fertil Steril       Date:  2011-04       Impact factor: 7.329

3.  Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study.

Authors:  Raoul C Reulen; Maurice P Zeegers; W Hamish B Wallace; Clare Frobisher; Aliki J Taylor; Emma R Lancashire; Dave L Winter; Mike M Hawkins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08       Impact factor: 4.254

4.  Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.

Authors:  Ashley H Woodson; Kimberly I Muse; Heather Lin; Michelle Jackson; Danielle N Mattair; Leslie Schover; Terri Woodard; Laurie McKenzie; Richard L Theriault; Gabriel N Hortobágyi; Banu Arun; Susan K Peterson; Jessica Profato; Jennifer K Litton
Journal:  Oncologist       Date:  2014-06-20

Review 5.  Chemotherapy-induced damage to ovary: mechanisms and clinical impact.

Authors:  Giuliano Bedoschi; Paula Andrea Navarro; Kutluk Oktay
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

6.  National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.

Authors:  Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-14       Impact factor: 5.742

Review 7.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

8.  Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer.

Authors:  Anne-Marie Charpentier; Amy Lee Chong; Genevieve Gingras-Hill; Sameera Ahmed; Candemir Cigsar; Abha A Gupta; Ellen Greenblatt; David C Hodgson
Journal:  J Cancer Surviv       Date:  2014-05-09       Impact factor: 4.442

9.  Photoperiod-dependent modulation of anti-Müllerian hormone in female Siberian hamsters, Phodopus sungorus.

Authors:  Esther W Kabithe; Ned J Place
Journal:  Reproduction       Date:  2008-03       Impact factor: 3.906

Review 10.  Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium.

Authors:  Wendy van Dorp; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Marry M van den Heuvel-Eibrink; Marleen H van den Berg; Jennifer M Levine; Eline van Dulmen-den Broeder; Natascia di Iorgi; Assunta Albanese; Saro H Armenian; Smita Bhatia; Louis S Constine; Andreas Corrias; Rebecca Deans; Uta Dirksen; Clarisa R Gracia; Lars Hjorth; Leah Kroon; Cornelis B Lambalk; Wendy Landier; Gill Levitt; Alison Leiper; Lillian Meacham; Alesandro Mussa; Sebastian J Neggers; Kevin C Oeffinger; Alberto Revelli; Hanneke M van Santen; Roderick Skinner; Andrew Toogood; William H Wallace; Riccardo Haupt
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.